# Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

> **NCT00381238** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00381238
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-20
- **Primary completion:** 2009-02-01
- **Final completion:** 2009-02-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381238, "Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00381238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*